Clinical presentation, radiographic workup and endoscopic workup
| Characteristic | N | % |
| CTCAE grade of diarrhea | ||
| Grade 0 | 17 | 12.32 |
| Grade 1 | 22 | 15.94 |
| Grade 2 | 32 | 23.19 |
| Grade 3 | 58 | 42.03 |
| Grade 4 | 9 | 6.52 |
| Grade 5 | 0 | 0.00 |
| Clinical suspicion of ICI enterocolitis | 122 | 88.41 |
| Contrast Administered | ||
| Intravenous and oral | 66 | 47.82 |
| Intravenous only | 53 | 38.41 |
| Oral only | 9 | 6.52 |
| No contrast | 10 | 7.25 |
| Time from last ICI dose to endoscopy (days) | ||
| Median | 25.50 | |
| IQR | 16–55 | |
| Endoscopy type | ||
| EGD | 20 | 14.49 |
| Flexible sigmoidoscopy | 68 | 49.28 |
| Flexible sigmoidoscopy/EGD | 17 | 12.32 |
| Colonoscopy | 26 | 18.84 |
| Colonoscopy/EGD | 7 | 5.07 |
| Inflammation on endoscopy | 80 | 57.97 |
CTCAE, Common Terminology Criteria for Adverse Events; EGD, Esophagogastroduodenoscopy; ICI, immune checkpoint inhibitor.;